BioCentury

INTRODUCTION

Letter from the Editor

PART 1

Imperative of COVID

PART 2

Addressing disparities

PART 3

Data sharing

PART 4

Master protocols

PART 5

Pandemic preparedness

ARTICLE | Product Development

Biopharmas must address the reality of racial disparities in health outcomes exposed by COVID-19

COVID-19 shows why biopharmas need to build racial equity into their drug development mindset

By C. simone fishburn, editor in chief, and Steve Usdin, Washington Editor
September 8, 2020 11:04 PM UTC

This is the second article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development and address the urgent healthcare chasms exposed by the crisis.

2020 has rung the alarm bell for biopharmas to address racial disparities in health outcomes.  ...